PMID: 6404150Apr 1, 1983Paper

Possible contribution of encainide metabolites to the long-term antiarrhythmic efficacy of encainide

The American Journal of Cardiology
R A WinkleD C Harrison

Abstract

To establish long-term efficacy and the relation between drug plasma concentration and antiarrhythmic response, 12 patients with encainide-responsive frequent complex ventricular ectopic activity underwent 1 year of therapy with encainide. Twenty-four hour ambulatory electrocardiograms were obtained at baseline and every 2 months. Drug withdrawal with concomitant plasma sampling and electrocardiographic monitoring was performed at 6 and 12 months. Average group premature ventricular contraction (PVC) suppression during the year was 97 to 99%, with nearly total suppression of pairs and salvos. The most common adverse effects were transient visual disturbances and dizziness or lightheadedness. During a dose interval (6 to 12 hours) the concentration of encainide metabolites exceeded that of encainide by several-fold. The median time of arrhythmia return after drug withdrawal was 12 to 14 hours. At the time of arrhythmia return encainide was generally no longer detectable but the average concentration of O-demethylencainide and 3 methoxy-O-demethylencainide was 72 +/- 49 and 172 +/- 74 ng/ml, respectively. It is concluded that encainide therapy is extremely effective for continuous long-term suppression of complex ventricular arrh...Continue Reading

References

Nov 1, 1979·European Journal of Clinical Pharmacology·H Kesteloot, R Stroobandt
Sep 1, 1979·The American Journal of Cardiology·M SamiD C Harrison
Jul 1, 1981·The American Journal of Cardiology·M SamiR F DeBusk
Nov 1, 1981·American Heart Journal·R A WinkleD Ross
Apr 1, 1982·The American Journal of Cardiology·W M JackmanE N Prystowsky

❮ Previous
Next ❯

Citations

Jun 1, 1990·Cardiovascular Drugs and Therapy·P Jaillon
Aug 29, 1986·The American Journal of Cardiology·D M RodenR L Woosley
Aug 29, 1986·The American Journal of Cardiology·D C HarrisonB D Quart
Dec 1, 1988·Clinical Pharmacy·M S ChowD Hilleman
Apr 30, 1987·The American Journal of Cardiology·R L Woosley, D M Roden
Aug 15, 1990·Biochemical Pharmacology·H K JajooI A Blair
Oct 1, 1989·Pacing and Clinical Electrophysiology : PACE·R LemeryD Roy
Apr 28, 1988·The New England Journal of Medicine·R L WoosleyD M Roden
Jan 1, 1986·Drug Intelligence & Clinical Pharmacy·A E Wehmeyer, R L Thomas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.